Optinose Inc (OPTN)

$0.68

+0.01

(+2.1%)▲

Market is closed - opens 7 PM, 04 Oct 2024

Performance

  • $0.67
    $0.69
    $0.68
    downward going graph

    1.44%

    Downside

    Day's Volatility :3.34%

    Upside

    1.92%

    downward going graph
  • $0.65
    $2.10
    $0.68
    downward going graph

    4.41%

    Downside

    52 Weeks Volatility :69.05%

    Upside

    67.62%

    downward going graph

Returns

PeriodOptinose IncIndex (Russel 2000)
3 Months
-34.46%
0.0%
6 Months
-50.01%
0.0%
1 Year
-45.64%
0.0%
3 Years
-77.62%
-20.2%

Highlights

Market Capitalization
103.3M
Book Value
- $0.29
Earnings Per Share (EPS)
-0.34
Wall Street Target Price
3.5
Profit Margin
-54.5%
Operating Margin TTM
-31.96%
Return On Assets TTM
-9.89%
Return On Equity TTM
-1050.5%
Revenue TTM
75.1M
Revenue Per Share TTM
0.62
Quarterly Revenue Growth YOY
5.3%
Gross Profit TTM
67.0M
EBITDA
-18.5M
Diluted Eps TTM
-0.34
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.23
EPS Estimate Next Year
-0.09
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
-0.05

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Optinose Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 414.71%

Current $0.68
Target $3.50

Company Financials

FY18Y/Y Change
Revenue
7.1M
↑ 4261.11%
Net Income
-106.7M
↑ 118.11%
Net Profit Margin
-1.5K%
↑ 28676.75%
FY19Y/Y Change
Revenue
34.6M
↑ 390.18%
Net Income
-108.9M
↑ 2.14%
Net Profit Margin
-314.59%
↑ 1195.08%
FY20Y/Y Change
Revenue
49.1M
↑ 41.83%
Net Income
-98.3M
↓ 9.74%
Net Profit Margin
-200.2%
↑ 114.39%
FY21Y/Y Change
Revenue
74.7M
↑ 51.99%
Net Income
-81.7M
↓ 16.96%
Net Profit Margin
-109.37%
↑ 90.83%
FY22Y/Y Change
Revenue
76.3M
↑ 2.18%
Net Income
-76.4M
↓ 6.44%
Net Profit Margin
-100.16%
↑ 9.21%
FY23Y/Y Change
Revenue
71.0M
↓ 6.93%
Net Income
-35.5M
↓ 53.55%
Net Profit Margin
-49.99%
↑ 50.17%
Q1 FY23Q/Q Change
Revenue
11.8M
↓ 43.2%
Net Income
-18.7M
↑ 7.63%
Net Profit Margin
-157.47%
↓ 74.37%
Q2 FY23Q/Q Change
Revenue
19.5M
↑ 64.22%
Net Income
2.6M
↓ 114.08%
Net Profit Margin
13.5%
↑ 170.97%
Q3 FY23Q/Q Change
Revenue
19.8M
↑ 1.9%
Net Income
-9.3M
↓ 453.92%
Net Profit Margin
-46.88%
↓ 60.38%
Q4 FY23Q/Q Change
Revenue
19.9M
↑ 0.21%
Net Income
-10.0M
↑ 7.24%
Net Profit Margin
-50.17%
↓ 3.29%
Q1 FY24Q/Q Change
Revenue
14.9M
↓ 25.09%
Net Income
-14.1M
↑ 41.14%
Net Profit Margin
-94.54%
↓ 44.37%
Q2 FY24Q/Q Change
Revenue
20.5M
↑ 37.7%
Net Income
-7.6M
↓ 46.11%
Net Profit Margin
-37.0%
↑ 57.54%
FY18Y/Y Change
Total Assets
217.0M
↓ 10.01%
Total Liabilities
98.4M
↑ 13.55%
FY19Y/Y Change
Total Assets
172.7M
↓ 20.43%
Total Liabilities
111.1M
↑ 12.9%
FY20Y/Y Change
Total Assets
188.8M
↑ 9.36%
Total Liabilities
182.0M
↑ 63.89%
FY21Y/Y Change
Total Assets
166.1M
↓ 12.04%
Total Liabilities
187.8M
↑ 3.2%
FY22Y/Y Change
Total Assets
144.2M
↓ 13.16%
Total Liabilities
200.8M
↑ 6.92%
FY23Y/Y Change
Total Assets
107.7M
↓ 25.3%
Total Liabilities
194.3M
↓ 3.24%
Q1 FY23Q/Q Change
Total Assets
114.9M
↓ 20.31%
Total Liabilities
188.7M
↓ 6.04%
Q2 FY23Q/Q Change
Total Assets
106.1M
↓ 7.71%
Total Liabilities
175.7M
↓ 6.88%
Q3 FY23Q/Q Change
Total Assets
101.4M
↓ 4.39%
Total Liabilities
179.0M
↑ 1.87%
Q4 FY23Q/Q Change
Total Assets
107.7M
↑ 6.23%
Total Liabilities
194.3M
↑ 8.55%
Q1 FY24Q/Q Change
Total Assets
83.7M
↓ 22.3%
Total Liabilities
182.9M
↓ 5.87%
Q2 FY24Q/Q Change
Total Assets
131.9M
↑ 57.54%
Total Liabilities
174.7M
↓ 4.48%
FY18Y/Y Change
Operating Cash Flow
-91.8M
↑ 157.54%
Investing Cash Flow
-1.7M
↓ 29.76%
Financing Cash Flow
59.6M
↓ 74.77%
FY19Y/Y Change
Operating Cash Flow
-90.8M
↓ 1.09%
Investing Cash Flow
-557.0K
↓ 67.04%
Financing Cash Flow
37.5M
↓ 37.01%
FY20Y/Y Change
Operating Cash Flow
-86.2M
↓ 5.08%
Investing Cash Flow
-546.0K
↓ 1.97%
Financing Cash Flow
83.8M
↑ 123.32%
FY21Y/Y Change
Operating Cash Flow
-76.9M
↓ 10.75%
Investing Cash Flow
-62.0K
↓ 88.64%
Financing Cash Flow
43.3M
↓ 48.31%
FY22Y/Y Change
Operating Cash Flow
-67.7M
↓ 12.07%
Investing Cash Flow
-63.0K
↑ 1.61%
Financing Cash Flow
51.4M
↑ 18.73%
Q1 FY23Q/Q Change
Operating Cash Flow
-10.5M
↓ 40.74%
Investing Cash Flow
-79.0K
↑ 2533.33%
Financing Cash Flow
162.0K
↓ 99.68%
Q2 FY23Q/Q Change
Operating Cash Flow
-12.5M
↑ 19.66%
Investing Cash Flow
-79.0K
↑ 0.0%
Financing Cash Flow
-1000.0
↓ 100.62%

Technicals Summary

Sell

Neutral

Buy

Optinose Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Optinose Inc
Optinose Inc
-30.9%
-50.01%
-45.64%
-77.62%
-89.21%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-8.7%
-18.7%
1.08%
10.99%
24.69%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
1.07%
26.37%
24.25%
40.35%
40.35%
Zoetis Inc.
Zoetis Inc.
1.95%
15.39%
11.7%
-1.39%
50.33%
Viatris Inc.
Viatris Inc.
-2.97%
-2.81%
17.84%
-14.89%
-30.05%
Catalent, Inc.
Catalent, Inc.
-0.02%
6.58%
40.56%
-52.95%
23.65%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Optinose Inc
Optinose Inc
NA
NA
NA
-0.23
-10.5
-0.1
NA
-0.29
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
33.7
33.7
0.26
4.57
0.16
0.12
NA
24.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
32.94
32.94
1.49
0.36
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
37.45
37.45
2.64
5.82
0.49
0.14
0.01
10.94
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.68
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.89
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Optinose Inc
Optinose Inc
Buy
$103.3M
-89.21%
NA
-54.5%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$11.5B
24.69%
33.7
16.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$48.2B
40.35%
32.94
9.66%
Zoetis Inc.
Zoetis Inc.
Buy
$87.2B
50.33%
37.45
26.29%
Viatris Inc.
Viatris Inc.
Hold
$13.6B
-30.05%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$11.0B
23.65%
211.02
-23.81%

Insights on Optinose Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 14.88M → 20.49M (in $), with an average increase of 27.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -14.06M → -7.58M (in $), with an average increase of 85.6% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 40.6% return, outperforming this stock by 86.2%

  • Vs NBIX

    In the last 3 years, Optinose Inc has experienced a drawdown of -77.6%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 24.7%

Institutional Holdings

  • Nantahala Capital Management, LLC

    17.80%

  • FMR Inc

    10.63%

  • MVM Partners LLC

    9.69%

  • Great Point Partners LLC

    9.10%

  • Rosalind Advisors, Inc.

    5.01%

  • Kingdon Capital Management LLC

    3.71%

Company Information

optinose, inc., established in 2010 and headquartered in yardley, pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ent and allergy specialists. our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. we are unified by a shared mission: to improve lives. we do this while also creating great value for the healthcare system and great outcomes for our stakeholders. as innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. we operate with an overarching commitment to doing what is right. we are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a fo

Organization
Optinose Inc
Employees
132
CEO
Dr. Ramy A. Mahmoud M.D., M.P.H.
Industry
Health Services

Discover More

FAQs